Diclofenac diethylamine 2.32% gel
DrugDiclofenac diethylamine 2.32% gel twice daily
NCT Number: NCT00573768
This study will evaluate the efficacy of diclofenac diethylamine 2.32% gel in the treatment of acute ankle sprain.
Looking for future studies?
Notify Me18 year–75 year
All sexes
Interventional
Phase 2
Novartis Investigative Site, Bad Bramstedt, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Other protocol-defined inclusion/exclusion criteria may apply
Diclofenac diethylamine 2.32% gel twice daily
Vehicle 2 times daily
Diclofenac diethylamine 2.32% gel once daily / Vehicle once daily
Time frame: change from baseline (on day 1) to day 5
Pain on movement: visual analogue scale (VAS) with anchors at 0 mm (no pain) and 100 mm (extreme pain)
Novartis
Industry
A Randomized, Double-blind, Multi-center, Vehicle-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Diclofenac Diethylamine 2.32% Gel Applied Once or Twice Daily in Patients With Acute Ankle Sprain
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT00680784
Ankle Injuries, Ankle Sprain
Birmingham, Alabama, United States
View Trial DetailsNCT00601471
Ankle Injuries, Ankle Sprain
Charlottesville, Virginia, United States
View Trial DetailsNCT00732017
Ankle Injuries, Ankle Sprain
Bucaramanga, Santander Department, Colombia
View Trial DetailsNCT07655973
Ankle Injuries, Ankle Sprain
Lahore, Punjab Province, Pakistan
View Trial Details